Olivia Marie Thompson Davies, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Vascular Malformations | 3 | 2022 | 464 | 1.190 |
Why?
|
Collagen Diseases | 1 | 2024 | 39 | 0.950 |
Why?
|
Skin Abnormalities | 2 | 2023 | 59 | 0.870 |
Why?
|
Needlestick Injuries | 1 | 2022 | 71 | 0.790 |
Why?
|
Rhabdomyosarcoma, Embryonal | 1 | 2022 | 100 | 0.750 |
Why?
|
Pruritus | 1 | 2024 | 377 | 0.740 |
Why?
|
Skin Diseases, Vascular | 1 | 2021 | 41 | 0.740 |
Why?
|
Nevus, Epithelioid and Spindle Cell | 1 | 2020 | 70 | 0.670 |
Why?
|
Rhabdomyosarcoma | 1 | 2022 | 358 | 0.640 |
Why?
|
Oral Ulcer | 1 | 2019 | 96 | 0.640 |
Why?
|
Pemphigoid, Bullous | 1 | 2019 | 114 | 0.600 |
Why?
|
Dermatology | 3 | 2024 | 914 | 0.580 |
Why?
|
Mouth Mucosa | 1 | 2019 | 426 | 0.560 |
Why?
|
Neurocutaneous Syndromes | 3 | 2022 | 53 | 0.520 |
Why?
|
Renal Dialysis | 1 | 2024 | 1786 | 0.490 |
Why?
|
Skin Neoplasms | 3 | 2023 | 5797 | 0.440 |
Why?
|
Vascular Diseases | 1 | 2021 | 1160 | 0.420 |
Why?
|
Skin Diseases | 1 | 2021 | 1088 | 0.420 |
Why?
|
Skin Diseases, Genetic | 2 | 2024 | 49 | 0.400 |
Why?
|
Autoimmune Diseases | 1 | 2019 | 2244 | 0.290 |
Why?
|
Aortic Coarctation | 2 | 2019 | 282 | 0.280 |
Why?
|
Eye Abnormalities | 2 | 2019 | 241 | 0.280 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2022 | 3599 | 0.260 |
Why?
|
Lentigo | 1 | 2022 | 37 | 0.210 |
Why?
|
Hypertension | 1 | 2022 | 8499 | 0.200 |
Why?
|
GTP-Binding Protein alpha Subunits | 1 | 2022 | 102 | 0.200 |
Why?
|
GTP-Binding Protein alpha Subunits, Gq-G11 | 1 | 2022 | 143 | 0.190 |
Why?
|
Class Ia Phosphatidylinositol 3-Kinase | 1 | 2021 | 76 | 0.180 |
Why?
|
Wisconsin | 1 | 2020 | 122 | 0.180 |
Why?
|
Accidents, Occupational | 1 | 2022 | 249 | 0.180 |
Why?
|
Cafe-au-Lait Spots | 1 | 2020 | 19 | 0.180 |
Why?
|
Limb Deformities, Congenital | 1 | 2021 | 136 | 0.180 |
Why?
|
Methotrexate | 2 | 2024 | 1719 | 0.170 |
Why?
|
Dapsone | 1 | 2019 | 56 | 0.170 |
Why?
|
Exanthema | 1 | 2024 | 504 | 0.170 |
Why?
|
Mentors | 1 | 2024 | 660 | 0.160 |
Why?
|
Psoriasis | 2 | 2024 | 938 | 0.150 |
Why?
|
Child | 10 | 2024 | 79818 | 0.150 |
Why?
|
Germ Cells | 1 | 2022 | 635 | 0.150 |
Why?
|
Hamartoma | 1 | 2019 | 235 | 0.140 |
Why?
|
Extremities | 1 | 2022 | 865 | 0.140 |
Why?
|
Diagnosis, Differential | 3 | 2020 | 12951 | 0.130 |
Why?
|
Dermatitis, Atopic | 1 | 2023 | 716 | 0.130 |
Why?
|
Neurofibromatosis 1 | 1 | 2020 | 560 | 0.120 |
Why?
|
Leadership | 1 | 2024 | 1371 | 0.120 |
Why?
|
Congenital Abnormalities | 1 | 2019 | 704 | 0.120 |
Why?
|
Hemangioma | 1 | 2019 | 727 | 0.120 |
Why?
|
Humans | 21 | 2024 | 758406 | 0.120 |
Why?
|
Rare Diseases | 1 | 2019 | 619 | 0.120 |
Why?
|
Research | 1 | 2021 | 1976 | 0.100 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2021 | 2443 | 0.100 |
Why?
|
Kidney Failure, Chronic | 1 | 2024 | 2457 | 0.100 |
Why?
|
Health Care Reform | 1 | 2020 | 1245 | 0.090 |
Why?
|
Skin | 2 | 2020 | 4464 | 0.080 |
Why?
|
Genetic Testing | 1 | 2021 | 3530 | 0.080 |
Why?
|
Education, Medical, Graduate | 1 | 2020 | 2359 | 0.080 |
Why?
|
Recurrence | 1 | 2019 | 8426 | 0.070 |
Why?
|
Male | 6 | 2024 | 358747 | 0.060 |
Why?
|
Melanoma | 1 | 2022 | 5691 | 0.060 |
Why?
|
Consensus | 2 | 2024 | 3099 | 0.060 |
Why?
|
Syndrome | 2 | 2020 | 3262 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3076 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3196 | 0.050 |
Why?
|
Female | 6 | 2024 | 390323 | 0.050 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2020 | 9273 | 0.050 |
Why?
|
Dermatitis | 1 | 2024 | 200 | 0.050 |
Why?
|
Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 2022 | 223 | 0.050 |
Why?
|
Severity of Illness Index | 1 | 2019 | 15785 | 0.050 |
Why?
|
Pandemics | 1 | 2020 | 8611 | 0.040 |
Why?
|
Internship and Residency | 1 | 2020 | 5865 | 0.040 |
Why?
|
Dermatologic Agents | 1 | 2024 | 308 | 0.040 |
Why?
|
Mosaicism | 1 | 2022 | 465 | 0.040 |
Why?
|
Neurofibromin 1 | 1 | 2020 | 190 | 0.040 |
Why?
|
Acne Vulgaris | 1 | 2024 | 356 | 0.040 |
Why?
|
Adolescent | 3 | 2024 | 87892 | 0.040 |
Why?
|
International Cooperation | 1 | 2024 | 1430 | 0.040 |
Why?
|
Antineoplastic Agents | 1 | 2020 | 13591 | 0.040 |
Why?
|
Nervous System Malformations | 1 | 2019 | 244 | 0.040 |
Why?
|
Risk Factors | 1 | 2022 | 73809 | 0.030 |
Why?
|
Retrospective Studies | 2 | 2020 | 80168 | 0.030 |
Why?
|
Middle Aged | 2 | 2024 | 219568 | 0.030 |
Why?
|
Gene Deletion | 1 | 2020 | 2666 | 0.030 |
Why?
|
Abnormalities, Multiple | 1 | 2019 | 1414 | 0.030 |
Why?
|
Neoplasms | 1 | 2020 | 22032 | 0.020 |
Why?
|
Germ-Line Mutation | 1 | 2020 | 1840 | 0.020 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2021 | 2858 | 0.020 |
Why?
|
Genetic Association Studies | 1 | 2020 | 2717 | 0.020 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2020 | 2895 | 0.020 |
Why?
|
Molecular Targeted Therapy | 1 | 2020 | 2796 | 0.020 |
Why?
|
Child, Preschool | 2 | 2024 | 42062 | 0.020 |
Why?
|
Infant | 2 | 2020 | 36055 | 0.020 |
Why?
|
Age Factors | 1 | 2019 | 18358 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2020 | 26183 | 0.010 |
Why?
|
Quality of Life | 1 | 2020 | 13285 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2019 | 25956 | 0.010 |
Why?
|
Signal Transduction | 1 | 2021 | 23342 | 0.010 |
Why?
|
Mutation | 1 | 2021 | 29915 | 0.010 |
Why?
|
Young Adult | 1 | 2019 | 58808 | 0.010 |
Why?
|
Adult | 1 | 2019 | 219935 | 0.000 |
Why?
|